tiprankstipranks
Trending News
More News >
HealthCare Global Enterprises Ltd. (IN:HCG)
:HCG
India Market
Advertisement

HealthCare Global Enterprises Ltd. (HCG) AI Stock Analysis

Compare
1 Followers

Top Page

IN:HCG

HealthCare Global Enterprises Ltd.

(HCG)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 4o)
Rating:61Neutral
Price Target:
₹653.00
▲(1.35% Upside)
The stock score is primarily driven by strong financial performance, characterized by revenue growth and profitability improvements. However, overvaluation concerns and technical indicators suggesting overbought conditions pose significant risks, balancing the overall score to a moderate level.

HealthCare Global Enterprises Ltd. (HCG) vs. iShares MSCI India ETF (INDA)

HealthCare Global Enterprises Ltd. Business Overview & Revenue Model

Company DescriptionHealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2021, it operated 23 cancer centers, including 1 center of excellence in Bengaluru, 2 freestanding diagnostic centers, and 1 day care chemotherapy center across India, as well as 1 cancer center in Africa. The company was founded in 1989 and is based in Bengaluru, India.
How the Company Makes MoneyHCG generates revenue primarily through the provision of medical services related to cancer treatment. Its key revenue streams include patient fees for consultations, diagnostics, and treatment procedures encompassing chemotherapy, radiation therapy, and surgery. The company also earns income from its laboratory services and imaging centers. Additionally, HCG benefits from partnerships and collaborations with pharmaceutical companies and research institutions, which contribute to its research and development initiatives and provide further revenue opportunities. The company's strategic expansion into tier 2 and tier 3 cities in India helps in increasing its patient base and enhancing its revenue potential.

HealthCare Global Enterprises Ltd. Financial Statement Overview

Summary
HealthCare Global Enterprises Ltd. has demonstrated strong revenue growth and improving profitability margins. However, the company faces challenges with decreasing net income and a leveraged balance sheet, indicating potential financial stability risks.
Income Statement
75
Positive
HealthCare Global Enterprises Ltd. has shown a strong revenue growth trajectory over the years. The company improved its revenue by 17.35% from 2024 to 2025. The gross profit margin stands at 52.11% and net profit margin at 2.00% for 2025, with a noticeable improvement in profitability metrics like EBIT and EBITDA margins, which are at 7.93% and 19.06% respectively. However, the net income has decreased compared to 2024, indicating potential operational challenges.
Balance Sheet
68
Positive
The company shows a moderately balanced financial structure with a debt-to-equity ratio of 1.99, indicating reliance on debt. The equity ratio at 26.02% reflects a reasonable level of equity financing. Return on Equity is low at 4.81%, suggesting limited profitability for equity holders. Overall, the balance sheet indicates a stable but leveraged position.
Cash Flow
70
Positive
HealthCare Global Enterprises Ltd. has demonstrated consistent positive operating cash flows, showing operational efficiency. The Operating Cash Flow to Net Income ratio is robust at 7.14, indicating strong cash flow generation relative to net income. Free Cash Flow has shown a growth of 9.39% from the previous year, reflecting healthy cash management. However, the Free Cash Flow to Net Income ratio at 2.44 highlights potential concerns in cash flow efficiency.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue22.18B22.18B18.90B16.76B13.83B10.04B
Gross Profit10.24B11.56B9.80B3.52B7.01B5.04B
EBITDA4.22B4.23B3.50B3.06B3.41B474.52M
Net Income444.10M444.10M481.55M293.49M537.33M-1.93B
Balance Sheet
Total Assets35.43B35.43B27.07B23.16B22.20B20.36B
Cash, Cash Equivalents and Short-Term Investments3.53B3.53B3.03B1.97B2.04B1.66B
Total Debt18.37B18.37B12.74B9.01B9.15B9.78B
Total Liabilities25.53B25.53B18.42B14.47B13.36B13.22B
Stockholders Equity9.22B9.22B8.26B8.61B8.70B6.97B
Cash Flow
Free Cash Flow0.001.08B988.99M1.18B1.49B850.97M
Operating Cash Flow0.003.17B2.85B2.52B2.20B1.21B
Investing Cash Flow0.00-4.88B-2.26B-1.33B1.25B-1.71B
Financing Cash Flow0.00-424.40M-640.16M-1.40B-1.55B1.12B

HealthCare Global Enterprises Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price644.30
Price Trends
50DMA
645.44
Negative
100DMA
601.95
Positive
200DMA
559.13
Positive
Market Momentum
MACD
-0.95
Positive
RSI
41.05
Neutral
STOCH
26.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HCG, the sentiment is Neutral. The current price of 644.3 is below the 20-day moving average (MA) of 673.14, below the 50-day MA of 645.44, and above the 200-day MA of 559.13, indicating a neutral trend. The MACD of -0.95 indicates Positive momentum. The RSI at 41.05 is Neutral, neither overbought nor oversold. The STOCH value of 26.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:HCG.

HealthCare Global Enterprises Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
327.58B99.69156.88%0.78%-53.19%-94.01%
75
Outperform
725.97B83.598.68%0.11%14.04%32.99%
71
Outperform
354.66B66.3414.22%0.04%15.42%10.66%
65
Neutral
351.53B44.5521.79%0.26%12.09%-2.79%
61
Neutral
₹90.85B242.2216.85%-29.57%
61
Neutral
1.10T96.0511.47%0.13%32.65%8.86%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:HCG
HealthCare Global Enterprises Ltd.
644.30
217.65
51.01%
IN:ASTERDM
Aster DM Healthcare Ltd.
625.05
213.90
52.02%
IN:FORTIS
Fortis Healthcare Ltd.
932.40
334.86
56.04%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,123.25
129.10
12.99%
IN:MEDANTA
Global Health Limited
1,300.35
269.97
26.20%
IN:NH
Narayana Hrudayalaya Ltd.
1,724.35
522.43
43.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 31, 2025